Key facts
- This page summarizes Pascal Deschatelets's Form 4 filing for Apellis Pharmaceuticals, Inc. (APLS).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 30 Jan 2023, 15:47.
Pascal Deschatelets - 27 Jan 2023 Form 4 Insider Report for Apellis Pharmaceuticals, Inc. (APLS)
- Reporting relationship
- Chief Scientific Officer
- Issuer ticker
- APLS
- Reported as of
- 27 Jan 2023
- Net transaction value
- -$43,905
- SEC form
- 4
- Accepted by SEC
- 30 Jan 2023, 15:47:08 UTC
- Prior SEC filing
- 24 Jan 2023
- Next SEC filing
- 10 Feb 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ David Watson, attorney-in-fact for Pascal Deschatelets
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Pascal Deschatelets filed Form 4 for Apellis Pharmaceuticals, Inc. (APLS) on 30 Jan 2023.
Change
- Previous filing in this sequence was filed on 24 Jan 2023.
- Current net transaction value: -$43,905.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
APLS
transaction
Common Stock
Tax liability
- Transaction value
- $43,905
- Shares
- -832
- Change %
- -0.08%
- Price
- $52.77
- Shares after
- 1,000,256
- Date
- 27 Jan 2023
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This represents shares withheld for tax on a restricted stock unit release.